Business

Elicio Therapeutics to Present at the Bank of America Healthcare Conference

BOSTON, April 30, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that Robert Connelly, Chief Executive Officer, Christopher Haqq, MD, PhD, Executive Vice President, Head of Research and Development and Chief Medical Officer, Pete DeMuth, PhD, Chief Scientific Officer, and Preetam Shah, MBA, PhD, Chief Strategy and Financ

articleElicio Therapeutics, Inc.April 30, 20262/company/elicio-therapeutics-inc/news/elicio-therapeutics-to-present-at-the-bank-of-america-healthcare-conference
Elicio Therapeutics to Present at the Bank of America Healthcare Conference

About this update from Elicio Therapeutics, Inc.

[{"type":"image","alt":"Elicio Therapeutics Inc.","displaySize":"","headline":null,"caption":"Elicio Therapeutics Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":108,"url":"https://media.zenfs.com/en/globenewswire.com/cce9a5a17e9aa5fb6eff6b1fd10e2995"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/qeuRU9Dt4U9Q8E7L.P_kqQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE1MQ--/https://media.zenfs.com/en/globenewswire.com/cce9a5a17e9aa5fb6eff6b1fd10e2995","width":300,"height":108}},"lazy":false},{"type":"text","content":"BOSTON, April 30, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that Robert Connelly, Chief Executive Officer, Christopher Haqq, MD, PhD, Executive Vice President, Head of Research and Development and Chief Medical Officer, Pete DeMuth, PhD, Chief Scientific Officer, and Preetam Shah, MBA, PhD, Chief Strategy and Financial Officer, will participate in the upcoming Bank of America Healthcare Conference, taking place May 12-14, 2026, in Las Vegas, NV.","length":632,"tagName":"p"},{"type":"text","content":"Bank of America Healthcare Conference Format: Company presentationDate: Thursday, May 14, 2026Time: 12:20 PM ET","length":114,"tagName":"p"},{"type":"text","content":"The live webcast and replay of the presentation will be available HERE and on Elicio’s Events page for 90 days following the event.","length":131,"tagName":"p"},{"type":"text","content":"If you are interested in arranging a 1×1 meeting with management at the conference, please contact your Bank of America representative.","length":135,"tagName":"p"},{"type":"text","content":"About Elicio Therapeutics ","length":25,"tagName":"p"},{"type":"text","content":"Elicio Therapeutics, Inc. (Nasdaq: ELTX) is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of high-prevalence cancers, including mKRAS-positive pancreatic and colorectal cancers. Elicio intends to build on recent clinical successes in the personalized cancer immunotherapy space to develop effective, off-the-shelf immunotherapies. Elicio’s Amphiphile (“AMP”) technology aims to enhance the education, activation and amplification of cancer-specific T cells relative to conventional...

More updates from Elicio Therapeutics, Inc.

Bank of AmericaElicio Therapeutics, Inc.Chief Executive OfficerChief Medical Officercolorectal cancersimmunotherapiescancer immunotherapyElicio TherapeuticsElicio Therapeutics, Incbiotechnology companyChief Scientific Officerclinical development